share_log

Goldman Sachs Maintains Buy on Roivant Sciences, Raises Price Target to $18

Goldman Sachs Maintains Buy on Roivant Sciences, Raises Price Target to $18

高盛维持对Roivant Sciences的买入,将目标股价上调至18美元
Moomoo 24/7 ·  04/03 11:18

Goldman Sachs analyst Corinne Jenkins maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $16 to $18.

高盛分析师科琳娜·詹金斯维持Roivant Sciences(纳斯达克股票代码:ROIV)的买入并将目标股价从16美元上调至18美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发